5 Menopause Research Updates That Could Shape Care
New research suggests a synergy between hormone therapy and GLP-1 weight-loss medications for women navigating menopause.
58 trends tracked about this subject — the full history, oldest to newest below.
New research suggests a synergy between hormone therapy and GLP-1 weight-loss medications for women navigating menopause.
Novo's next-generation obesity drug CagriSema showed 25 percent weight loss in women in late-stage analysis.
Recent studies link popular GLP-1 weight-loss drugs to unexpected dermatological side effects like nail detachment and hair loss.
Recent coverage links GLP-1 medications like Ozempic and Wegovy to legal action involving vision loss alongside contrasting studies.
A growing wave of coverage examines newly reported links between popular GLP-1 medications and rare instances of severe vision loss.
Federal regulators face mounting scrutiny as unapproved weight-loss drugs and new safety warnings enter public focus.
Popular weight loss medications face new scrutiny as coverage connects them to unusual nail and hair complications.
7 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
2 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
Recent studies link weight-loss medications like Ozempic and Wegovy to unexpected hair and nail side effects.
7 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
Real-world study data reveals patients switching from obesity injections to Novo Nordisk's oral Wegovy pill continue to lose weight.
GLP-1 medications are shifting from clinical obesity treatments for patients to lifestyle products for customers, amid a surge in oral pill options.
Novo Nordisk strikes a $1.3 billion deal with Nanexa to secure long-acting obesity injection technology.
4 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
New reports warn that discontinuing GLP-1 weight-loss medications like Ozempic, Mounjaro, and Wegovy may increase the risk of heart attack and stroke.
Major drugmakers Novo Nordisk and Eli Lilly face numerous lawsuits alleging popular GLP-1 medications cause sudden vision loss.
1 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
1 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
1 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Novo Nordisk shares slide despite aggressive obesity targets as investors demand a broader long-term strategy.
Recent studies indicate that popular weight-loss treatments manufactured by Novo Nordisk and Eli Lilly retain efficacy at reduced doses.
A large genetic study connects GLP-1 receptor activation to improved mental well-being.
1 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
New research indicates that GLP-1 medications like Ozempic and Wegovy may significantly reduce the frequency of asthma attacks and COPD flare-ups.
A new observational study links weight regain following the use of obesity medications to an increased risk of suicidal thoughts.
Novo Nordisk faces a divergent clinical outlook as its pediatric obesity trials succeed while heart drug programs for CKD suffer setbacks.
Novo Nordisk's Wegovy shows weight-loss results in young children during trial data releases.
A new study suggests a genetic link between the use of GLP-1 weight-loss medications and increased hair loss risks for certain men.
Recent studies indicate that GLP-1 weight loss medications may worsen or accelerate hair loss in men.
A growing cultural and medical debate is emerging over the use of GLP-1 medications, focusing on the tension between clinical benefits and social stigma.
Experts call for safer weight loss methods as public and medical attention intensifies around the use and effectiveness of GLP-1 medications.
5 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
3 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
New scientific discoveries regarding brain circuits may redefine the understood mechanism of GLP-1 weight loss drugs like Ozempic and Wegovy.
3 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
Regulators receive hundreds of reports linking popular weight-loss drugs to deaths.
4 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
4 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
Patients are facing restricted access to GLP-1 drugs like Ozempic and Wegovy due to high costs and restrictive insurance policies.
Australian regulators and medical reports link GLP-1 weight-loss drugs like Ozempic to a rare and severe risk of permanent vision loss.
A Georgia woman has joined a growing lawsuit connecting popular GLP-1 weight loss drugs to a rare and blinding eye condition.
Recent medical reviews suggest users of GLP-1 weight-loss medications may face significant weight regain after stopping treatment.
A 54-year-old woman's emergency room hospitalization after a GLP-1 overdose highlights rising public safety concerns.
Recent data indicates that 11% of the American population is now utilizing GLP-1 weight loss medications such as Wegovy.
Wegovy weight‑loss pill hits UK shelves today, sparking a predicted rush of tens of thousands of users.
Medicare initiates a pilot program providing coverage for GLP-1 weight-loss medications beginning July 1, 2026.
Parents are increasingly administering weight-loss medications like Wegovy to elementary school children as young as six to combat obesity.
5 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
6 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
2 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
16 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
New research indicates that GLP-1 obesity medications may provide unexpected benefits for male fertility by increasing testosterone and sperm quality.
New research indicates that patients taking GLP-1 weight loss drugs are reducing their physical activity levels.
GLP-1 weight-loss drugs are exposing a hidden health crisis: nutrient deficiencies linked to rapid weight loss
US employers may halt GLP-1 drug coverage in 2027 amid rising costs and usage spikes